{'fraction_non_alphanumeric': 0.029783393501805054, 'fraction_numerical': 0.01444043321299639, 'mean_word_length': 5.230337078651686, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Value of adjuvant chemotherapy in infiltrating tumors of the bladder].

Two populations of patients with invasive epithelial bladder carcinoma are considered. Group A includes 26 patients with P greater than or equal to 2 MO lesions who, prospectively, received adjuvant postoperative chemotherapy with methotrexate, adriamycin, 5 fluoro-uracil and cisplatinum. Group B includes 24 patients treated in the same institution but without chemotherapy. In group A, 6 patients died from distant metastases. One death was not related to disease progression. The 3-year-disease-free survival rate is 67.7%. Acceptability and tolerance of chemotherapy are satisfactory. In group B, a retrospective analysis after the same radiosurgical approach found in one patient a regional recurrence leading to death 5 years after diagnosis. Twenty patients died from distant metastases. The 3-year-disease-free survival rate is 18.5%. No treatment related deaths occurred in either group. Although biased selection in such conditions is inevitable, the benefit of adjuvant chemotherapy looks rather impressive and encouraging.